Altogether, this research offers both molecular insights and pre-clinical evidence, supporting the use of pharmacological drugs targeting the m6A methyltransferase METTL3 as a valuable combination therapy to enhance anti-tumor immune responses and improve the effectiveness of anti-PD1 immune checkpoint blockage therapy (Fig. 1). The gene discussed is METTL3; the disease is neoplasm.